Navigation Links
New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
Date:9/16/2009

HOERSHOLM, Denmark and SAN DIEGO, California, September 16 /PRNewswire/ --

- Denmark-Based Santaris Pharma A/S Appoints Leading RNA Industry Expert Art Levin Ph.D. as President of US Operations and Chief Development Officer

- Utilizing its Proprietary RNA Chemistry - Locked Nucleic Acid (LNA) -and Drug Discovery Engine, the US Subsidiary Aims to Foster Relationships With New Partners, Increase Visibility With Capital Markets and Attract Leading Scientists

- Santaris Pharma A/S is First Company to Advance a microRNA-Targeted Drug into Human Clinical Trials; SPC3649 Targets miR-122 for the Treatment of Hepatitis C

- Recently Announced Strategic Alliance With Shire Demonstrates LNA is Rapidly Becoming the Chemistry-of-Choice and Adds to the Growing List of mRNA and microRNA Drug Discovery and Development Partnerships That Include Wyeth, GlaxoSmithKline and Enzon for a Range of Diseases

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced it has established operations in the United States. Internally and through its partners, the Company has a robust drug development pipeline including programs to treat metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

Increasing interest, new collaborations and breakthrough advancements utilizing the Company's proprietary RNA-based Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine led Santaris Pharma A/S, headquartered in Denmark, to establish US-based operations in San Diego, California.

To spearhead the US expansion, Santaris Pharma A/S has appointed leading RNA industry expert Arthur A. Levin, PhD, as President of its US operations. In addition, Dr. Levin will hold global responsibility as Vice President and Chief Development Officer
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)
2. Californias International Stem Cell Collaborations Must Be Based on Scientific Merit, Consumer Group Says
3. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
4. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
5. Aurora Biofuels Breakthrough Doubles CO2 Uptake and Fuel Production
6. Research breakthrough will lead to more accurate weather forecasts
7. OMT announces a breakthrough in the development of a novel human antibody platform
8. New drugs faster from natural compounds: A UC San Diego breakthrough
9. Expanding Indianas Breakthroughs in Health Information Technology (Exibhit Indiana): Initiative to Advance the States Health IT National Leadership and Assets Launched to Bring More Awareness to Sector
10. Light sensor breakthrough could enhance digital cameras
11. DNA2.0 Awarded US Patents for Breakthrough Gene Optimization Technology -- Company's Unique Algorithm Enables Expression Yields up to 50 Times Greater than Competing Approaches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... and LONDON, Dec. 15 ... Thomson Pharma ® has become the first drug ... protocol and outcome information. This highly anticipated new ... customers this month. ,, Thomson ... intelligence from registries, publications, press releases, conferences, and ...
(Date:12/15/2009)... The Prinz Law Office has announced the launch of ... businesses secure legal services in the current economic climate. ... them the opportunity to finance legal services over a ... requiring any equity in their start-up companies. The ... for fixed montly payment arrangements over 6 to 12 ...
(Date:12/14/2009)... Dec. 14 Vermillion, Inc. (Pink ... announced William C. Wallen, Ph.D. Chief Scientific ... for IDEXX Laboratories, will be joining its ... bankruptcy plan. ,, "Bill brings more ... in diagnostics and biotechnology," said Gail Page, ...
(Date:12/14/2009)... Rep. Patrick Kennedy Joins with State Biotech ... Leadership in Research and Development while Boosting ... Industry ,, PROVIDENCE, R.I., Dec. 14 ... prominent leaders in research, medicine and biotechnology ... Facility to discuss the importance of medical ...
Breaking Biology Technology:Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4
... DUBLIN, May 4 Circ Pharma Limited ("Circ ... they have entered into a,Development Agreement to develop ... moderate to moderately severe pain. , ... drug delivery,technology enabling once daily dosing. Circ,s technology ...
... May 4 Arno Therapeutics, Inc. (OTC Bulletin Board: ... today announced that it has voluntarily filed a Form ... order to deregister its common stock under the Securities ... effective immediately, Arno,s obligation to file periodic and other ...
... Medivation, Inc. (Nasdaq: MDVN ) ... with management to discuss first quarter 2009 financial results and ... at 4:30 p.m. Eastern Time. A press release for ... after markets close on May 11, 2009.Interested parties may call ...
Other Biology Technology:Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009 2
(Date:12/14/2009)... at Rice University and Baylor College of Medicine (BCM) ... in real time with MRI as it homes in ... and kills them with heat. The all-in-one particle is ... called "theranostics" that develops technologies physicians can use to ... The research is available online in the journal ...
(Date:12/14/2009)... clean-burning, renewable fuel that could help wean the nation ... ozone, compared with gasoline, especially in winter, according to ... Ozone production from both gasoline and E85, a blend ... is greater in warm sunny weather than during the ... and sunlight contribute to ozone formation. But E85 produces ...
(Date:12/14/2009)... Engineering Society (BMES) have founded a new journal ... CVET is a forum for research on ... The first issue of the new quarterly journal will ... publications at Springer, Annals of Biomedical Engineering ... Cardiovascular Engineering and Technology will present a wide ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3Biomedical Engineering Society's new journal to be published by Springer 2Third National Annual Salary Survey for Medical Interpreters Underway 56903 1Third National Annual Salary Survey for Medical Interpreters Underway 56903 2RZN Nutraceuticals Receives United States Patent 26 Trademark Office Notice of Allowance for Proprietary HerbaZorb 28TM 29 Absorption and Delivery Sy 56901 1RZN Nutraceuticals Receives United States Patent 26 Trademark Office Notice of Allowance for Proprietary HerbaZorb 28TM 29 Absorption and Delivery Sy 56901 2Modelesque Abs Without the Crunches Are Now Possible With the High Definition Tummy Tuck 56900 1Modelesque Abs Without the Crunches Are Now Possible With the High Definition Tummy Tuck 56900 2
... Calif. Oct. 6, 2008 Complete Genomics Inc., ... formal launch as the world,s first provider of large-scale ... was established in March 2006, has been operating in ... For the past two and a half years, Complete ...
... before it has a chance to take root and ... discoveries in cancer prevention. Leading experts from around the ... this expanding and promising new field, with the hope ... , To help you take advantage of the meeting,s ...
... in a previously identified gene, a variation that likely ... lip. It is the first time a genetic variant ... both cleft lip and palate. , The study provides ... eventually help with diagnosis, prevention and treatment of cleft ...
Other Biology News:Complete Genomics launches, becomes world's first large-scale human genome sequencing company 2Complete Genomics launches, becomes world's first large-scale human genome sequencing company 3Complete Genomics launches, becomes world's first large-scale human genome sequencing company 4Study finds genetic variant plays role in cleft lip 2Study finds genetic variant plays role in cleft lip 3
Dopamine D2 and D3 receptor, human and possibly mouse. AB1502 detects 40 ng of dopamine receptor peptide by ELISA. AB1502 is not neutralizing....
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Adhesion Molecule Antibodies...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Biology Products: